Welcome to performance-materials.net, the one-stop source of information about the advanced materials industry worldwide. Coverage includes features, news and events information about engineering plastics, composites and ceramics. Membership gives full access to daily updates plus over five years of industry archives.


Following completion of the active clinical part of a Phase III study of an implant for treating central precocious puberty (CPP), or the early onset of puberty, manufacturer, Valera Pharmaceuticals Inc, plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) during this second quarter of 2006.